Applied DNA Sciences (NASDAQ:APDN) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Applied DNA Sciences (NASDAQ:APDN – Get Free Report) in a report issued on Monday. The brokerage set a “sell” rating on the technology company’s stock.

Separately, HC Wainwright decreased their target price on Applied DNA Sciences from $7.00 to $1.50 and set a “buy” rating for the company in a research report on Monday, June 10th.

Check Out Our Latest Stock Analysis on Applied DNA Sciences

Applied DNA Sciences Stock Down 1.6 %

Shares of NASDAQ APDN opened at $0.43 on Monday. The stock has a market cap of $424,242.00, a PE ratio of -0.03 and a beta of 0.08. Applied DNA Sciences has a 52-week low of $0.33 and a 52-week high of $37.20. The business has a 50-day moving average price of $1.22 and a 200 day moving average price of $6.97.

Applied DNA Sciences (NASDAQ:APDN – Get Free Report) last announced its earnings results on Friday, May 10th. The technology company reported ($5.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($4.60) by ($0.71). The firm had revenue of $0.93 million during the quarter, compared to analyst estimates of $0.90 million. Applied DNA Sciences had a negative net margin of 222.33% and a negative return on equity of 306.32%. Sell-side analysts anticipate that Applied DNA Sciences will post -2.95 earnings per share for the current year.

Hedge Funds Weigh In On Applied DNA Sciences

A hedge fund recently bought a new stake in Applied DNA Sciences stock. Silverberg Bernstein Capital Management LLC bought a new stake in shares of Applied DNA Sciences, Inc. (NASDAQ:APDN – Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 98,301 shares of the technology company’s stock, valued at approximately $61,000. Silverberg Bernstein Capital Management LLC owned about 0.72% of Applied DNA Sciences as of its most recent filing with the SEC. Institutional investors own 22.22% of the company’s stock.

About Applied DNA Sciences

(Get Free Report)

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.

Read More

• Five stocks we like better than Applied DNA Sciences
• 3 Ways To Invest In Coffee, Other Than Drinking It
• Top 3 Defense Stocks That Should Be on Your Radar
• How Can Investors Benefit From After-Hours Trading
• Why This Banking Stock Might Be Nearing the Bottom of Its Cycle
• Are Penny Stocks a Good Fit for Your Portfolio?
• MarketBeat Week in Review – 7/8 – 7/12

Receive News & Ratings for Applied DNA Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Applied DNA Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.

You might be interested in: